CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM.
ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM.
这些发现为 CMV 感染促进 GBM 免疫抑制的潜在机制提供了新见解,并为 GBM 患者提供了一种新的潜在免疫治疗策略。
背景:胶质母细胞瘤(GBM)是成人致命性原发脑恶性肿瘤。既往研究显示,巨细胞病毒(CMV)是 GBM 肿瘤发生和侵袭性的危险因素,但 CMV 感染如何影响 GBM 肿瘤微环境中的免疫细胞仍知之甚少。迄今也几乎没有针对 CMV 的工程化 T 细胞受体(TCR)T 细胞用于 GBM 的研究。 方法:采用免疫电子显微镜、免疫荧光和微滴数字 PCR 评估 GBM 患者肿瘤组织的 CMV 感染状态。对 CMV 感染的 GBM 进行单细胞 RNA 测序,研究 CMV 对 GBM 免疫微环境的影响;应用 CellChat 分析 GBM 肿瘤微环境中的细胞间相互作用。此外,采用单细胞 TCR/B 细胞受体(BCR)测序和 Grouping of Lymphocyte Interactions with Paratope Hotspots 2 算法获取 CMV 特异性 TCR 序列。通过基因工程将 CMV-TCR 导入 CMV 感染 GBM 患者来源的原代 T 细胞,并用流式细胞术检测体外 T 细胞比例和细胞毒状态。 结果:研究在 CMV 感染的 GBM 中发现两个新型免疫细胞亚群:CD68+SOX2+ 双阳性肿瘤相关巨噬细胞和 FXYD6+ T 细胞。双阳性 TAM 或癌细胞与 T 细胞之间的相互作用主要集中于 FXYD6+ T 细胞,而非调节性 T 细胞(Treg);进一步发现 FXYD6+ T 细胞是一类新型免疫抑制性 T 细胞。CMV-TCR-T 细胞在人体来源原位 GBM 小鼠模型中显示显著治疗效果。 结论:研究结果揭示了 CMV 感染促进 GBM 免疫抑制的潜在机制,并为 GBM 患者提供了一种新型潜在免疫治疗策略。
BACKGROUND: Glioblastoma (GBM) is a fatal primary brain malignancy in adults. Previous studies have shown that cytomegalovirus (CMV) is a risk factor for tumorigenesis and aggressiveness for glioblastoma. However, little is known about how CMV infection affects immune cells in the tumor microenvironment of GBM. Furthermore, there has been almost no engineered T-cell receptor (TCR)-T targeting CMV for GBM research to date. METHODS: We evaluated the CMV infection status of patients with GBM's tumor tissue by immune electron microscopy, immunofluorescence, and droplet digital PCR. We performed single-cell RNA sequencing for CMV-infected GBM to investigate the effects of CMV on the GBM immune microenvironment. CellChat was applied to analyze the interaction between cells in the GBM tumor microenvironment. Additionally, we conducted single-cell TCR/B cell receptor (BCR) sequencing and Grouping of Lymphocyte Interactions with Paratope Hotspots 2 algorithms to acquire specific CMV-TCR sequences. Genetic engineering was used to introduce CMV-TCR into primary T cells derived from patients with CMV-infected GBM. Flow cytometry was used to measure the proportion and cytotoxicity status of T cells in vitro. RESULTS: We identified two novel immune cell subpopulations in CMV-infected GBM, which were bipositive CD68 + SOX2 + tumor-associated macrophages and FXYD6 + T cells. We highlighted that the interaction between bipositive TAMs or cancer cells and T cells was predominantly focused on FXYD6 + T cells rather than regulatory T cells (Tregs), whereas, FXYD6 + T cells were further identified as a group of novel immunosuppressive T cells. CMV-TCR-T cells showed significant therapeutic effects on the human-derived orthotopic GBM mice model. CONCLUSIONS: These findings provided an insight into the underlying mechanism of CMV infection promoting the GBM immunosuppression, and provided a novel potential immunotherapy strategy for patients with GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。